Another study combines lymphodepletion with anti-CD45 mAb with a vaccine generated from autologous DC and Epstein Barr virus (EBV)-infected lymphoblastoid cell lines transduced with an LMP1/LMP2-expressing adenoviral vector, which are irradiated, and then used to stimulate and expand autologous CTL to produce LMP1-/LMP2-specific CTL ex vivo, for the treatment of EBV+-nasopharyngeal carcinoma (NCT00515957). Here, PSMB9 is linked to nasopharyngeal carcinoma.